Patrys, an Australian therapeutic antibody development company, has announced the appointment of Dr. Charmaine Gittleson as the Chairman of the Board of Directors.
Dr. Gittleson is the former Chief Medical Officer of CSL Limited with more than 20 years of experience in pharmaceutical development in the USA and Australia. Dr. Gittleson’s expertise spans many aspects of the pharmaceutical industry, from drug development and clinical research through to strategic planning and executive management. She has been involved in drug development programs across a wide range of different therapeutic areas, and has successfully worked with regulators in key markets such as the US, EU, Asia Pacific, Japan and South America.
Dr. Gittleson joins Patrys as the company completes the last remaining stages of preclinical development for its first-in-class anti-cancer antibody PAT-DX1, which is scheduled to commence first in human studies in the second half of 2023. In parallel, Patrys is in the process of establishing a commercial-scale production process for its second deoxymab, PAT‑DX3, which is a full‑sized IgG antibody capable of delivering therapeutic payloads both across the blood brain barrier, and into the nucleus.